Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Corcept Therapeutics (CORT) EPS (Basic) (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed EPS (Basic) for 16 consecutive years, with -$0.3 as the latest value for Q1 2026.

  • For Q1 2026, EPS (Basic) fell 257.89% year-over-year to -$0.3; the TTM value through Mar 2026 reached $0.46, down 63.78%, while the annual FY2025 figure was $0.95, 29.63% down from the prior year.
  • EPS (Basic) hit -$0.3 in Q1 2026 for Corcept Therapeutics, down from $0.24 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.45 in Q3 2024 and bottomed at -$0.3 in Q1 2026.
  • Average EPS (Basic) over 5 years is $0.23, with a median of $0.27 recorded in 2023.
  • Year-over-year, EPS (Basic) skyrocketed 100.0% in 2023 and then tumbled 257.89% in 2026.
  • Corcept Therapeutics' EPS (Basic) stood at $0.15 in 2022, then skyrocketed by 100.0% to $0.3 in 2023, then decreased by 3.33% to $0.29 in 2024, then decreased by 17.24% to $0.24 in 2025, then tumbled by 225.0% to -$0.3 in 2026.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$0.3, $0.24, and $0.19 for Q1 2026, Q4 2025, and Q3 2025 respectively.